NASDAQ:KNSA

Kiniksa Pharmaceuticals . Class A Stock Predictions

Healthcare > Biotechnology

Buy KNSA

*Your capital is at risk

$59.49

+2.36 (+4.13%)

At Close: Jun 23, 2026

Currently predicting for Wed, 24 Jun 2026

KNSA Live board

Community Bull/Bear

Target Next close

Join the KNSA prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

KNSA Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For KNSA

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

KNSA Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT KINIKSA PHARMACEUTICALS LTD. CLASS A

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclo...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
IDYA $28.98	20.46%	Jun 12
DHI $146.71	6.39%	Jun 10
E ETD $20.67	4.79%	Jun 05
EAT $140.46	16.94%	Jun 05
OSW $24.00	17.08%	Jun 04

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by